Contrasting NewGenIvf Group (NASDAQ:NIVF) & Progyny (NASDAQ:PGNY)

Progyny (NASDAQ:PGNY) and NewGenIvf Group (NASDAQ:NIVF) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Volatility and Risk

Progyny has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, NewGenIvf Group has a beta of 0.2, indicating that its share price is 80% less volatile than the S&P 500.

Earnings and Valuation

This table compares Progyny and NewGenIvf Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Progyny	$1.09 billion	1.24	$62.04 million	$0.63	23.81
NewGenIvf Group	$5.14 million	0.54	$130,000.00	N/A	N/A

Progyny has higher revenue and earnings than NewGenIvf Group.

Profitability

This table compares Progyny and NewGenIvf Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Progyny	5.54%	11.97%	8.43%
NewGenIvf Group	N/A	N/A	N/A

Insider and Institutional Ownership

94.9% of Progyny shares are held by institutional investors. Comparatively, 66.2% of NewGenIvf Group shares are held by institutional investors. 12.3% of Progyny shares are held by company insiders. Comparatively, 31.8% of NewGenIvf Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Progyny and NewGenIvf Group, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Progyny	0	7	5	0	2.42
NewGenIvf Group	0	0	0	0	N/A

Progyny presently has a consensus target price of $27.73, indicating a potential upside of 84.85%. Given Progyny’s higher probable upside, analysts plainly believe Progyny is more favorable than NewGenIvf Group.

Summary

Progyny beats NewGenIvf Group on 10 of the 11 factors compared between the two stocks.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

About NewGenIvf Group

A SPAC I Acquisition Corp. is a blank check company. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or related business combination with one or more businesses. A SPAC I Acquisition Corp. is based in Singapore.